Home » Authors » Jim Shrine

Articles by Jim Shrine

European Sector Rallying Cry: Comebacks, Consolidation

March 12, 2003

Companies Urged To Shore Up Until Sector Regains Favor

Sep. 11, 2002

Companies Urged To Shore Up Until Sector Regains Favor

Sep. 11, 2002

European Biotech Struggling, Industry Waiting For Upswing

Sep. 10, 2002

European Biotech Struggling, Industry Waiting For Upswing

Sep. 10, 2002

Finding Hot’ Biotech Investments Still Means Looking At Leaders

March 21, 2002

Finding Hot’ Biotech Investments Still Means Looking At Leaders

March 21, 2002

Investors In Tight Market Looking At Hybrid Platform/Product Firms

March 20, 2002

Investors In Tight Market Looking At Hybrid Platform/Product Firms

March 20, 2002

Large-Cap Companies Doing Well In Maturing Industry s Bifurcation

Jan. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 11, 2024.
Boryung invests $10M in Intuitive Machines for outer space R&D
BioWorld
Following its $60 million investment in Axiom Space Inc. last year, Boryung Co. Ltd. made a $10 million private placement in Intuitive Machines Inc. to grow its...
Phase II Huntington’s tie-up with Novartis could edge $3B for PTC
BioWorld
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the firm’s Huntington’s disease program with...
Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal
BioWorld
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.